At the time of writing, Vaxcyte Inc [PCVX] stock is trading at $48.04, down -0.97%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PCVX shares have gain 6.00% over the last week, with a monthly amount glided 8.34%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vaxcyte Inc [NASDAQ: PCVX] stock has seen the most recent analyst activity on January 07, 2026, when Needham reiterated its Buy rating and also boosted its price target to $110 from $90. Previously, Goldman started tracking the stock with Neutral rating on September 12, 2025, and set its price target to $38. On April 22, 2025, Cantor Fitzgerald initiated with a Overweight rating. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $135 on December 20, 2024. Mizuho initiated its recommendation with a Buy and recommended $69 as its price target on December 07, 2023. In a note dated January 03, 2023, Needham reiterated an Buy rating on this stock and boosted its target price from $52 to $58.
For the past year, the stock price of Vaxcyte Inc fluctuated between $27.66 and $93.77. Currently, Wall Street analysts expect the stock to reach $77 within the next 12 months. Vaxcyte Inc [NASDAQ: PCVX] shares were valued at $48.04 at the most recent close of the market. An investor can expect a potential return of 60.28% based on the average PCVX price forecast.
Analyzing the PCVX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.21 and Total Capital is -0.27. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Vaxcyte Inc [NASDAQ:PCVX] has a current ratio of 8.83. As well, the Quick Ratio is 8.83, while the Cash Ratio is 1.41.
Transactions by insiders
Recent insider trading involved Dhaliwal Harpreet S., Chief Technical Ops Officer, that happened on Dec 31 ’25 when 9743.0 shares were sold. Officer, HARPREET DHALIWAL completed a deal on Dec 31 ’25 to buy 9743.0 shares. Meanwhile, SVP, FINANCE Cowan Elvia sold 11623.0 shares on Dec 23 ’25.
